94% of researchers rate our articles as excellent or good
Learn more about the work of our research integrity team to safeguard the quality of each article we publish.
Find out more
ORIGINAL RESEARCH article
Front. Genome Ed.
Sec. Genome Editing in Human Health and Disease
Volume 7 - 2025 | doi: 10.3389/fgeed.2025.1558432
This article is part of the Research TopicApplication and Advantages of Genome Editing Technology in Anti-AgingView all articles
Mapping the therapeutic landscape of CRISPR-Cas9 for combating age-related diseases
Provisionally accepted- 1West China Hospital, Sichuan University, Chengdu, China
- 2Key Laboratory of Bio resource and Eco-environment, College of Life Science, Sichuan University, Chengdu, Sichuan Province, China
- 3West China Second University Hospital, Sichuan University, Chengdu, Sichuan Province, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
CRISPR-Cas9 (clustered regularly interspaced short palindromic repeats-associated protein 9) has emerged as a transformative genome-editing tool with significant therapeutic potential for age-related diseases, including Alzheimer's disease, Parkinson's disease, cardiovascular disorders, and osteoporosis. This study presents a bibliometric analysis of CRISPR-Cas9 research in age-related diseases, identifying key contributors, major research hotspots, and critical technological advancements.While promising applications have been demonstrated in gene repair, functional regulation, and molecular interventions, significant barriers persist, including offtarget effects, low delivery efficiency, and limited editing in non-dividing cells.Ethical concerns over germline editing and gaps in long-term safety data further complicate clinical translation. Future directions emphasize the development of highprecision Cas9 variants, homology-directed repair-independent tools, and efficient delivery systems, alongside the establishment of international regulatory frameworks and multicenter clinical trials. These efforts are essential to fully realize the potential of CRISPR-Cas9 in addressing the global health challenges of aging.
Keywords: age-related diseases, bibliometric analysis, CRISPR-Cas9, Genome editing, Gene Therapy
Received: 10 Jan 2025; Accepted: 19 Mar 2025.
Copyright: © 2025 He, Wang, Tan, Zhang, Yu and Jiang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence:
Chao Yu, West China Second University Hospital, Sichuan University, Chengdu, 610041, Sichuan Province, China
Xiaoqin Jiang, West China Second University Hospital, Sichuan University, Chengdu, 610041, Sichuan Province, China
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.